Aligos.png
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
June 05, 2024 02:30 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics...
Aligos.png
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
May 22, 2024 16:05 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics...
Aligos.png
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
May 21, 2024 08:00 ET | Aligos Therapeutics
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc....
Aligos.png
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
May 07, 2024 16:05 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics...
Aligos.png
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
April 30, 2024 16:05 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Aligos.png
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
April 25, 2024 16:05 ET | Aligos Therapeutics
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting SOUTH SAN FRANCISCO, Calif., April 25,...
Aligos.png
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
April 25, 2024 08:00 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Aligos.png
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
April 09, 2024 08:00 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Aligos.png
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
April 03, 2024 08:00 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Aligos.png
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
March 27, 2024 08:00 ET | Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...